A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab - Trial NCT06322667
Access comprehensive clinical trial information for NCT06322667 through Pure Global AI's free database. This phase not specified trial is sponsored by Eisai Co., Ltd. and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 5000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eisai Co., Ltd.
Eisai Inc.
Timeline & Enrollment
N/A
Dec 22, 2023
Dec 31, 2027
Primary Outcome
Number of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H),Number of Participants With Interruption or Discontinuation of Lecanemab After Onset of ARIA
Summary
The primary purpose of this study is to investigate the characteristics of amyloid related
 imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g.,
 continuation, interruption) after the onset of ARIA in routine clinical practice in
 participants treated with lecanemab.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06322667
Non-Device Trial